Two Sigma Advisers
SCNI

Two Sigma Advisers’s Scinai Immunotherapeutics SCNI Stock Holding History

Two Sigma Advisers’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-111
Closed -$42K – 2663
2021
Q1 		$42K Buy
+111
New +$48.5K ﹤0.01% 2507

Other funds holding SCNI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Two Sigma Advisers's SCNI Position: Q2 2021 in Review

Two Sigma Advisers sold out of Scinai Immunotherapeutics (SCNI) in Q2 2021, closing a stake of 111 shares — an estimated $42K sold.

Two Sigma Advisers first reported a position in SCNI in Q1 2021 and held it in 1 quarter. The position peaked at $42K in Q1 2021. 16 funds tracked by Wall St. Rank hold SCNI as of Q2 2021.

  • Two Sigma Advisers reported no remaining Scinai Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 111 Scinai Immunotherapeutics shares in Q2 2021, an estimated $42K.
  • Two Sigma Advisers first reported a position in Scinai Immunotherapeutics in Q1 2021 and held it in 1 quarter.
  • Two Sigma Advisers's Scinai Immunotherapeutics position peaked at $42K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2021.

Based on Two Sigma Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.